These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 34396420)
1. Type I Interferon Signature in Chilblains Following SARS-CoV-2 mRNA Vaccine: A Case Report. Souaid K; Oulès B; Sohier P; Deschamps L; Aractingi S; Dupin N Acta Derm Venereol; 2021 Nov; 101(11):adv00589. PubMed ID: 34396420 [No Abstract] [Full Text] [Related]
2. BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2. Piccolo V; Bassi A; Argenziano G; Mazzatenta C; Cutrone M; Neri I; Grimalt R; Russo T J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):e493-e494. PubMed ID: 33914966 [No Abstract] [Full Text] [Related]
3. Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that 'COVID toes' are due to the immune reaction to SARS-CoV-2. Lesort C; Kanitakis J; Donzier L; Jullien D J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e630-e632. PubMed ID: 34131969 [No Abstract] [Full Text] [Related]
4. Chilblains and COVID-19-An Update on the Complexities of Interpreting Antibody Test Results, the Role of Interferon α, and COVID-19 Vaccines. Sun Q; Freeman EE JAMA Dermatol; 2022 Feb; 158(2):217-218. PubMed ID: 34935876 [No Abstract] [Full Text] [Related]
5. Chilblains and COVID-19-An Update on the Complexities of Interpreting Antibody Test Results, the Role of Interferon α, and COVID-19 Vaccines-Reply. McCleskey PE; Lieberman A; Herrinton LJ JAMA Dermatol; 2022 Feb; 158(2):218-219. PubMed ID: 34935853 [No Abstract] [Full Text] [Related]
6. A Case of Chilblains-like Lesions Post SARS-CoV-2 Vaccine? Meara AS; Silkowski M; Quin K; Jarjour W J Rheumatol; 2021 Nov; 48(11):1754. PubMed ID: 34210829 [No Abstract] [Full Text] [Related]
8. Impaired type I interferon response in SARS-CoV-2 infection: looking through the cutaneous window. Bessis D Br J Dermatol; 2021 Jan; 184(1):11-12. PubMed ID: 33249567 [No Abstract] [Full Text] [Related]
9. COVID-19 pandemic-associated chilblains: more links for SARS-CoV-2 and less evidence for high interferon type I systemic response. Bessis D; Trouillet-Assant S; Secco LP; Bardin N; Blanc B; Blatière V; Chable-Bessia C; Delfour C; Girard C; Richard JC; Gros N; Le Moing V; Molinari N; Pallure V; Pisoni A; Raison-Peyron N; Reynaud E; Schwob É; Pescarmona R; Samaran Q; Willems M; Vincent T; Sofonea MT; Belot A; Tuaillon É Br J Dermatol; 2022 Dec; 187(6):1032-1035. PubMed ID: 35971922 [No Abstract] [Full Text] [Related]
10. Chilblains observed during the COVID-19 pandemic cannot be distinguished from classic, cold-related chilblains. De Greef A; Choteau M; Herman A; Bouzin C; Marot L; Dachelet C; Lelotte J; Hoton D; Dumoutier L; Baeck M Eur J Dermatol; 2022 May; 32(3):377-383. PubMed ID: 36065533 [TBL] [Abstract][Full Text] [Related]